TTY Biopharm Company Limited (TPEX: 4105)

TTY Biopharm Company Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2,658	2,621	2,357	2,222	2,224	2,422
Short-Term Investments	225.31	195.54	326.86	372.65	342.4	482.62
Cash & Short-Term Investments	2,883	2,817	2,684	2,595	2,566	2,905
Cash Growth	6.30%	4.93%	3.44%	1.12%	-11.66%	0.06%
Accounts Receivable	1,377	1,344	1,227	1,138	1,033	997.6
Other Receivables	66.94	28.81	29.68	13.62	16.48	119.75
Receivables	1,444	1,373	1,257	1,151	1,050	1,117
Inventory	1,438	1,096	1,039	955.01	1,111	858.69
Prepaid Expenses	62.25	79.02	49.89	46.96	64.15	48.31
Other Current Assets	35.93	6.36	5.37	1.15	8.01	45.3
Total Current Assets	5,863	5,370	5,035	4,749	4,799	4,974
Property, Plant & Equipment	2,269	2,287	2,433	2,519	2,585	2,394
Long-Term Investments	1,666	1,578	1,496	1,432	1,458	1,495
Other Intangible Assets	142.68	164.01	250.75	124.9	132.9	139.01
Long-Term Deferred Tax Assets	48.72	48.71	47.1	63.72	61.8	45.67
Other Long-Term Assets	407.23	426.94	337.89	407.19	324.72	504.42
Total Assets	10,645	9,875	9,601	9,296	9,361	9,553
Accounts Payable	304.28	294.66	289.4	187.27	159.44	181.28
Short-Term Debt	1,900	1,450	1,370	1,711	1,715	1,561
Current Portion of Long-Term Debt	400	-	418.85	407.91	16.54	355.93
Current Portion of Leases	7.02	5.86	3.92	7.62	-	-
Current Income Taxes Payable	120.49	156.97	149.52	150.39	110.13	188.86
Current Unearned Revenue	29.64	14.23	33.13	39.77	16.29	16.68
Other Current Liabilities	559.53	662.02	652.62	547.55	531.2	721.62
Total Current Liabilities	3,321	2,584	2,917	3,052	2,549	3,025
Long-Term Debt	-	400	9.6	4.15	412.05	16.31
Long-Term Leases	5.35	3.05	3.04	14.16	-	-
Long-Term Deferred Tax Liabilities	318.75	318.75	305.44	260.52	271.83	282.08
Other Long-Term Liabilities	2.44	35.83	91.03	146.23	4.7	3.72
Total Liabilities	3,674	3,369	3,367	3,529	3,283	3,384
Common Stock	2,487	2,487	2,487	2,487	2,487	2,487
Additional Paid-In Capital	317.02	316.62	312.18	311.88	338	338.51
Retained Earnings	3,344	3,182	2,925	2,568	2,759	2,705
Comprehensive Income & Other	61.95	-43.79	-64.78	-198.07	-133.71	40.14
Total Common Equity	6,210	5,941	5,658	5,168	5,450	5,571
Minority Interest	760.41	564.8	574.86	599.38	628.3	598.43
Shareholders' Equity	6,970	6,506	6,233	5,767	6,078	6,169
Total Liabilities & Equity	10,645	9,875	9,601	9,296	9,361	9,553
Total Debt	2,312	1,859	1,805	2,145	2,144	1,933
Net Cash (Debt)	570.62	957.65	878.78	450	422.47	971.46
Net Cash Growth	12.24%	8.97%	95.28%	6.52%	-56.51%	-30.58%
Net Cash Per Share	2.29	3.84	3.53	1.81	1.70	3.90
Filing Date Shares Outstanding	248.65	248.65	248.65	248.65	248.65	248.65
Total Common Shares Outstanding	248.65	248.65	248.65	248.65	248.65	248.65
Working Capital	2,542	2,787	2,118	1,698	2,250	1,949
Book Value Per Share	24.97	23.89	22.76	20.78	21.92	22.40
Tangible Book Value	5,819	5,777	5,408	5,043	5,317	5,432
Tangible Book Value Per Share	23.40	23.23	21.75	20.28	21.38	21.84
Land	902.9	902.9	902.9	902.9	902.9	816.17
Buildings	1,477	1,461	1,432	1,420	1,311	1,317
Machinery	1,420	1,432	1,418	1,359	1,234	1,183
Construction In Progress	19.14	8.95	77.09	95	323.33	149.79

Source: S&P Capital IQ. Standard template. Financial Sources.